Valuation: TScan Therapeutics, Inc.

Market Cap 69.27M 60.6M 55.88M 51.71M 98.14M 6.61B 99.78M 669M 262M 3.25B 260M 254M 11.25B P/E 2026 *
-1.21x
P/E 2027 * -1.15x
Enterprise Value -29.6M -25.89M -23.87M -22.09M -41.93M -2.82B -42.63M -286M -112M -1.39B -111M -109M -4.81B EV / Sales 2026 *
-3.92x
EV / Sales 2027 * -0.7x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -
06-22 TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation CI
06-22 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT
06-03 Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101 CI
05-06 TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-02 TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026 CI
03-04 TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
02-27 TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial RE
02-26 TScan Therapeutics, Inc. Completes Enrollment in Cohort C of Phase 1 AlloHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A03 CI
12-19 TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from NASDAQ Biotechnology Index CI
12-07 TScan Therapeutics Announces Positive Updated Data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition CI
11-14 Morgan Stanley Downgrades TScan Therapeutics to Equalweight From Overweight MT
11-12 TScan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-12 TScan Therapeutics Q3 revenue jumps RE
1 day-1.42%
Current month+7.13%
1 month+14.32%
6 months-10.26%
Current year+5.00%
1 week 1.01
Extreme 1.01
1.28
1 month 0.83
Extreme 0.8251
1.28
Current year 0.83
Extreme 0.8251
1.47
1 year 0.83
Extreme 0.8251
2.57
3 years 0.83
Extreme 0.8251
9.69
5 years 0.83
Extreme 0.8251
14.71
10 years 0.83
Extreme 0.8251
14.71
Manager TitleAgeSince
Chief Executive Officer 56 28/03/2023
Director of Finance/CFO 57 29/01/2024
Chief Tech/Sci/R&D Officer 50 08/04/2024
Director TitleAgeSince
Director/Board Member 68 23/03/2021
Director/Board Member 56 24/05/2023
Chairman 55 12/06/2024
Date Insider Type Main position Quantity % Market Cap.
05-20Free

Director

67,000 0.1200%
05-20Free

Director

67,000 0.1200%
05-20Free

Director

67,000 0.1200%
Change 5-day change 1-year change 3-year change Capi.($)
-1.42%0.00%-42.93%-51.39% 69.27M
-4.14%-8.06%+57.35%+117.24% 56.98B
+1.84%+1.65%+76.90%+95.68% 53.58B
-3.73%+2.51%+18.30%+460.51% 25.63B
-1.73%-2.67%-19.75%-14.90% 23.51B
+2.43%+5.86%+46.56%+0.42% 19.43B
-3.19%0.00%+33.99%-26.87% 18.12B
-6.84%+2.18%+203.03%+348.11% 16.46B
+8.74%+10.46%+47.66% - 14.13B
-1.26%+1.49%+24.76%+195.52% 14.35B
Average -0.97%+1.05%+44.59%+124.92% 24.23B
Weighted average by Cap. -1.24%+0.29%+54.82%+137.25%

Financials

2026 *2027 *
Net sales 7.56M 6.61M 6.1M 5.64M 10.71M 721M 10.89M 73.01M 28.62M 354M 28.37M 27.76M 1.23B 7.81M 6.83M 6.3M 5.83M 11.06M 745M 11.25M 75.42M 29.57M 366M 29.31M 28.67M 1.27B
Net income -115M -101M -92.83M -85.89M -163M -10.98B -166M -1.11B -436M -5.39B -432M -423M -18.68B -125M -109M -101M -93.16M -177M -11.91B -180M -1.21B -473M -5.85B -469M -458M -20.27B
Net Debt -98.87M -86.49M -79.76M -73.8M -140M -9.44B -142M -955M -374M -4.63B -371M -363M -16.05B -74.76M -65.4M -60.31M -55.8M -106M -7.14B -108M -722M -283M -3.5B -281M -275M -12.14B
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
139
Date Price Change Volume
10/07/26 $1.050 -0.94% 630,265
09/07/26 $1.060 -15.87% 1,266,274
08/07/26 $1.260 +17.76% 2,637,071
07/07/26 $1.070 +1.90% 606,643
06/07/26 $1.050 -0.94% 418,939
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.060USD
Average target price
6.000USD
Spread / Average Target
+466.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock